Lineage Cell Therapeutics (LCTX) Cash from Investing Activities (2010 - 2026)

Lineage Cell Therapeutics' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$2.3 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 222.23% year-over-year to -$2.3 million in Q1 2026; TTM through Mar 2026 was -$17.7 million, a 4719.07% decrease from a year earlier, with the FY2025 full-year figure at -$13.5 million, down 483.06% from the prior year.
• Cash from Investing Activities climbed to -$2.3 million in Q1 2026 per LCTX's latest filing, from -$15.3 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $19.2 million in Q2 2023 and bottomed at -$40.9 million in Q3 2022.
• The 5-year median for Cash from Investing Activities is -$14000.0 (2025), against an average of -$1.0 million.
• Across the five-year window, Cash from Investing Activities sank 60067.65% in 2022 and jumped 33634.78% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at -$5.1 million in 2022, then surged by 290.94% to $9.7 million in 2023, then tumbled by 72.95% to $2.6 million in 2024, then sank by 681.94% to -$15.3 million in 2025, then jumped by 84.83% to -$2.3 million in 2026.
• Per Business Quant, the three latest LCTX Cash from Investing Activities figures stand at -$2.3 million (Q1 2026), -$15.3 million (Q4 2025), and -$12000.0 (Q3 2025).